세계의 대사 치료제 시장 규모 조사 및 예측 : 약물 유형별, 적응증별, 지역별 분석(2023-2030년)

Global Metabolism Drugs Market is valued approximately at USD 16.10 billion in 2022 and is anticipated to grow with a growth rate of more than 6.50% over the forecast period 2023-2030. A metabolism drug refers to a medication or treatment that specifically targets and affects the body's metabolic processes. Metabolism encompasses the chemical reactions and processes that occur within cells to convert food and nutrients into energy, as well as the breakdown and elimination of waste products. A metabolism drug is designed to either stimulate or inhibit certain metabolic pathways in order to achieve desired therapeutic outcomes. These drugs can be used to regulate or enhance metabolism, manage conditions related to metabolic disorders, promote weight loss, or address specific metabolic dysfunctions. Metabolism drugs are developed through rigorous research and testing to ensure safety and efficacy in modulating the body's metabolic functions. Moreover, increasing prevalence of chronic disease and rising geriatric population are anticipated market drivers. Furthermore, growing pharmaceuticals industry and increasing medical tourism for advanced healthcare treatment fuel the market space during the forecast period 2023-2030.

The prevalence of noncommunicable diseases (NCDs) affecting diverse populations presents a significant growth opportunity for the metabolism drug market. According to the World Health Organization (WHO) in 2022, NCDs impact individuals of various age groups, regions, and nations, with 17 million premature NCD-related deaths occurring before the age of 70. Particularly concerning is that 86% of these premature deaths transpire in low and middle-income countries. Risk factors such as unhealthy diets, physical inactivity, tobacco exposure, and excessive alcohol consumption make people across different age groups susceptible to these conditions. Metabolism drugs play a crucial role in addressing these risk factors and can contribute to the prevention, management, and treatment of NCDs, benefiting individuals globally. According to the World Health Organization (WHO) in 2020, the population of individuals aged 60 years and above increased from 1 billion to 1.4 billion, with expectations of reaching a staggering 2.1 billion globally. Additionally, there is an anticipation of the number of individuals aged 60 years or older tripling between 2020 and 2050, accounting for approximately 426 million individuals. However, side effects & safety concerns and high cost of development may hamper market growth.

The key regions considered for the Global Metabolism Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the dominant region in the Metabolism Drug Market with largest market share. Firstly, the region boasts a robust pharmaceutical industry with advanced research and development capabilities, leading to the production of innovative metabolism drugs. Secondly, North America has a significant population affected by metabolic disorders, creating a substantial market demand for effective treatments. Additionally, the region benefits from well-established healthcare infrastructure, including advanced medical facilities and favorable reimbursement policies, ensuring widespread access to metabolism drugs. Lastly, the presence of key market players and research institutions focused on metabolic disorders further solidifies North America's position as a leader in the metabolism drug market. Asia Pacific is expected to be the fastest growing market for metabolism drugs due to factors such as a large and expanding population, improving healthcare infrastructure, rising disposable incomes, growing awareness of metabolic health, and government initiatives promoting healthcare advancement.

Major market player included in this report are:

• Merck Sharp & Dohme LLC
• Novartis AG
• Amicus Therapeutics Inc.
• AstraZeneca PLC.
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• GlaxoSmithKline PLC.
• Horizon Therapeutics PLC
• BioMarin Pharmaceutical Inc.

Recent Developments in the Market:

• In January 2023, Researchers from the University of Galway, affiliated with APC Microbiome Ireland, have created a new resource of digital microbes specifically focused on drug metabolism. This collection of over 7,000 digital microorganisms allows for computer simulations and predictions of metabolic changes in individuals, offering insights into how pharmacological treatments may function and how patients might respond. The tool holds significant potential for studying diseases such as inflammatory bowel, Parkinson's, and colorectal cancer, marking a significant milestone in understanding the human response to medical therapy.
• In March 2023, A team of researchers from the Indian Institute of Science Education and Research in Bhopal has developed an artificial intelligence (AI) system that can predict how the gut flora would metabolize various foods and medications. This web-based application focuses on the specific bacterial enzymes, processes, and bacteria involved in the digestion and absorption of food in the human gut. The system holds promise in understanding the complex interactions between gut flora and metabolism.

Global Metabolism Drugs Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimatio: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drug Type, Indication, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

• Antidiabetic Drugs
• Lipid Lowering Drugs
• Anti-Obesity Drugs
• Thyroid Hormone Drugs
• Others

By Indication:

• Diabetes
• Hyperlipidaemia
• Obesity
• Hypothyroidism

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Metabolism Drug Market, by region, 2020-2030 (USD Billion)
  • 1.2.2. Metabolism Drug Market, by Drug Type, 2020-2030 (USD Billion)
  • 1.2.3. Metabolism Drug Market, by Indication, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Metabolism Drug Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Metabolism Drug Market Dynamics

• 3.1. Metabolism Drug Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Growing prevalence of Chronic Disease
    • 3.1.1.2. Rising geriatric population
  • 3.1.2. Market Challenges
    • 3.1.2.1. High cost of metabolism drug
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Growing pharmaceuticals industry
    • 3.1.3.2. Increasing medical tourism

Chapter 4. Global Metabolism Drug Market: Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economic
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Metabolism Drug Market, by Drug Type

• 5.1. Market Snapshot
• 5.2. Global Metabolism Drug Market by Drug Type, Performance - Potential Analysis
• 5.3. Global Metabolism Drug Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
• 5.4. Metabolism Drug Market, Sub Segment Analysis
  • 5.4.1. Antidiabetic Drugs
  • 5.4.2. Lipid Lowering Drugs
  • 5.4.3. Anti-Obesity Drugs
  • 5.4.4. Thyroid Hormone Drugs
  • 5.4.5. Others

Chapter 6. Global Metabolism Drug Market, by Indication

• 6.1. Market Snapshot
• 6.2. Global Metabolism Drug Market by Indication, Performance - Potential Analysis
• 6.3. Global Metabolism Drug Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
• 6.4. Metabolism Drug Market, Sub Segment Analysis
  • 6.4.1. Diabetes
  • 6.4.2. Hyperlipidaemia
  • 6.4.3. Obesity
  • 6.4.4. Hypothyroidism

Chapter 7. Global Metabolism Drug Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Metabolism Drug Market, Regional Market Snapshot
• 7.4. North America Metabolism Drug Market
  • 7.4.1. U.S. Metabolism Drug Market
    • 7.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. Indication breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Metabolism Drug Market
• 7.5. Europe Metabolism Drug Market Snapshot
  • 7.5.1. U.K. Metabolism Drug Market
  • 7.5.2. Germany Metabolism Drug Market
  • 7.5.3. France Metabolism Drug Market
  • 7.5.4. Spain Metabolism Drug Market
  • 7.5.5. Italy Metabolism Drug Market
  • 7.5.6. Rest of Europe Metabolism Drug Market
• 7.6. Asia-Pacific Metabolism Drug Market Snapshot
  • 7.6.1. China Metabolism Drug Market
  • 7.6.2. India Metabolism Drug Market
  • 7.6.3. Japan Metabolism Drug Market
  • 7.6.4. Australia Metabolism Drug Market
  • 7.6.5. South Korea Metabolism Drug Market
  • 7.6.6. Rest of Asia Pacific Metabolism Drug Market
• 7.7. Latin America Metabolism Drug Market Snapshot
  • 7.7.1. Brazil Metabolism Drug Market
  • 7.7.2. Mexico Metabolism Drug Market
• 7.8. Middle East & Africa Metabolism Drug Market
  • 7.8.1. Saudi Arabia Metabolism Drug Market
  • 7.8.2. South Africa Metabolism Drug Market
  • 7.8.3. Rest of Middle East & Africa Metabolism Drug Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Merck Sharp & Dohme LLC
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. Novartis AG
  • 8.3.3. Amicus Therapeutics Inc.
  • 8.3.4. AstraZeneca PLC.
  • 8.3.5. Boehringer Ingelheim International GmbH
  • 8.3.6. Takeda Pharmaceutical Company Limited
  • 8.3.7. Sanofi S.A.
  • 8.3.8. GlaxoSmithKline PLC.
  • 8.3.9. Horizon Therapeutics PLC
  • 8.3.10. BioMarin Pharmaceutical Inc.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption